Company record · updated October 7, 2026
Avrobio Inc: 2 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs January 31, 2024 to April 30, 2024.
2observations
2source filings
2verified rows
2024-04-30most recent as-of date
Source rails for this company: N-PORT fund mark (2).
Reported by 1 filer: Fidelity Advisor Biotechnology Fund.
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2024-04-30 | price per share | 12.3991 USD | Fidelity Advisor Biotechnology Fund | VERIFIED | valUSD 1689994.6 / balance 136300.0 [unspecified] | 000175272424151078 |
| 2024-01-31 | price per share | 12.3991 USD | Fidelity Advisor Biotechnology Fund | VERIFIED | valUSD 1689994.6 / balance 136300.0 [unspecified] | 000175272424071829 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price.